Rigel Pharmaceuticals Inc
NASDAQ:RIGL
Rigel Pharmaceuticals Inc
Cash from Financing Activities
Rigel Pharmaceuticals Inc
Cash from Financing Activities Peer Comparison
Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors
Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Rigel Pharmaceuticals Inc
NASDAQ:RIGL
|
Cash from Financing Activities
$18.4m
|
CAGR 3-Years
13%
|
CAGR 5-Years
-24%
|
CAGR 10-Years
33%
|
|
Abbvie Inc
NYSE:ABBV
|
Cash from Financing Activities
-$17.2B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-17%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cash from Financing Activities
-$5.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
16%
|
CAGR 10-Years
-7%
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash from Financing Activities
$21B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
23%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash from Financing Activities
-$562.2m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-51%
|
CAGR 10-Years
N/A
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash from Financing Activities
-$1.8B
|
CAGR 3-Years
3%
|
CAGR 5-Years
-88%
|
CAGR 10-Years
N/A
|
See Also
What is Rigel Pharmaceuticals Inc's Cash from Financing Activities?
Cash from Financing Activities
18.4m
USD
Based on the financial report for Dec 31, 2023, Rigel Pharmaceuticals Inc's Cash from Financing Activities amounts to 18.4m USD.
What is Rigel Pharmaceuticals Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 10Y
33%
Over the last year, the Cash from Financing Activities growth was 180%. The average annual Cash from Financing Activities growth rates for Rigel Pharmaceuticals Inc have been 13% over the past three years , -24% over the past five years , and 33% over the past ten years .